Paclitaxel Protein-Bound Dosage
This dosage information may not include all the information needed to use Paclitaxel Protein-Bound safely and effectively. See additional information for Paclitaxel Protein-Bound.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Breast Cancer
260 mg/m2 administered intravenously over 30 minutes every 3 weeks
Renal Dose Adjustments
The effects of renal dysfunction on paclitaxel protein-bound particles has not been formally investigated.
Liver Dose Adjustments
The effects of hepatic dysfunction on paclitaxel protein-bound particles has not been formally investigated. The appropriate dose of paclitaxel protein-bound particles for patients with bilirubin greater than 1.5 mg/dL is not known.
Dose Adjustments
Paclitaxel protein-bound particles should not be administered to patients with metastatic breast cancer who have baseline neutrophil counts of less than 1,500 cells/mm3. Frequent peripheral blood cell counts should be performed on all patients receiving paclitaxel protein-bound particles in order to monitor the occurrence of bone marrow suppression (primarily neutropenia) which may be severe and result in infection. Patients should not be retreated with subsequent cycles of paclitaxel protein-bound particles until neutrophils recover to a level >1,500 cells/mm3 and platelets recover to a level >100,000 cells/mm3. If a patient has severe neutropenia (<500 cells/mm3 for seven days or more) during a course of therapy with paclitaxel protein-bound particles, then a dose reduction for subsequent courses of therapy is recommended.
Sensory neuropathy has been reported to occur frequently with the use of paclitaxel protein-bound particles. Grade 1 or 2 sensory neuropathy does not generally require dose modification. However, if grade 3 sensory neuropathy develops, treatment should be withheld until the sensory neuropathy subsides to grade 1 or 2. All subsequent courses should then be at a reduced dose.
Precautions
Because of the possibility of extravasation, close monitoring of the infusion site for possible infiltration during drug administration is recommended.
Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).
Dialysis
Data not available
